Biktarvy(Bictegrav/Emtricit/Tenofov Ala)
GILD
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Gilead Sciences, Inc.
$3.45B
Medicare cost, 2024
$3.45B
Medicare cost, 2024
Medicare drug plans spent $3.5 billion on Biktarvy (bictegrav/emtricit/tenofov ala) in 2024, for 840,473 prescriptions and refills filled by 92,204 patients. It ranks 13th among all drugs by Medicare drug plan spending. At about $4,111 per prescription it is a high-cost drug. Florida accounts for the most spending ($415.7 million, 12% of the total).
Medicare cost, 2024
$3.45B
+9.6% from 2023
Prescriptions
840K
$4,110.59 per claim
Patients
92K
28,169 prescribers
Total spending, 2024
$3.46B
$37,465.70 per patient
Questions and answers
How much does Medicare spend on Biktarvy?
Medicare prescription drug plans paid $3.45B for Biktarvy in 2024, for 840,473 prescriptions and refills to 92,204 patients (up 9.6% from 2023). The average cost per claim was $4,110.59.
Which state spends the most on Biktarvy?
Florida had the highest Medicare cost for Biktarvy in 2024: $415.7M for 103,739 claims, followed by New York ($396.9M).
Who prescribes Biktarvy the most?
Ronald Cathcart, internal medicine in Melbourne, FL, had the highest Medicare cost for Biktarvy in 2024: 1,591 claims costing $6.2M.
Who makes Biktarvy?
Biktarvy is made by Gilead Sciences, Inc. (GILD), listed in the Medicare spending data as Gilead Sciences.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Biktarvy was $3.46B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Biktarvy, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Ronald Cathcart Melbourne, FL | Internal Medicine | 1,591 | 153 | $6.2M |
| Dong Phuong H Nguyen San Francisco, CA | Pharmacist | 559 | 165 | $6.0M |
| Federico Hinestrosa Orlando, FL | Infectious Disease | 1,431 | 155 | $5.8M |
| Akinwale O Olatosi Camden, SC | Internal Medicine | 1,415 | 141 | $5.4M |
| Marc A Johnson Charlotte, NC | Internal Medicine | 1,217 | 126 | $5.0M |
| Sharon D Reiley Jacksonville, FL | Nurse Practitioner | 1,223 | 135 | $4.8M |
| Joseph C Gathe Jr. Houston, TX | Infectious Disease | 1,062 | 125 | $4.4M |
| Rosa O Diring Norfolk, VA | Nurse Practitioner | 1,059 | 124 | $4.3M |
| Jeffrey K Claus Albany, NY | Physician Assistant | 1,045 | 138 | $4.3M |
| Stephen A Renae Fort Lauderdale, FL | Infectious Disease | 1,137 | 153 | $4.3M |
| Jeena Mathew Bartow, FL | Nurse Practitioner | 1,060 | 159 | $4.0M |
| Harmeet S Gill Columbia, SC | Hospitalist | 995 | 101 | $3.8M |
| Rafael Martinez San Antonio, TX | Family Practice | 942 | 91 | $3.8M |
| Pamela L Burian Los Angeles, CA | Physician Assistant | 964 | 97 | $3.7M |
| Thomas P Poirier Gainesville, FL | Infectious Disease | 914 | 102 | $3.7M |
| Ellen Tedaldi Philadelphia, PA | Internal Medicine | 955 | 120 | $3.7M |
| Melissa M Stevenson Albany, GA | Nurse Practitioner | 972 | 138 | $3.7M |
| Tessa Gomez New York, NY | Internal Medicine | 954 | 125 | $3.7M |
| Alireza Farabi Las Vegas, NV | Internal Medicine | 902 | 147 | $3.7M |
| Gerald R Hamwi Los Angeles, CA | Family Practice | 951 | 92 | $3.7M |
| Michael Robinson Riverside, CA | Family Practice | 942 | 110 | $3.6M |
| Ethan T Dungan Birmingham, AL | Nurse Practitioner | 901 | 102 | $3.5M |
| Ann E Stapleton Palm Springs, CA | Internal Medicine | 809 | 91 | $3.5M |
| Terry L Wilder Orlando, FL | Nurse Practitioner | 837 | 109 | $3.5M |
| John W Hogan Washington, DC | Internal Medicine | 871 | 101 | $3.5M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 21,585 | 685,942 | 75,752 | $2.70B |
| 2023 | 25,068 | 756,254 | 83,793 | $3.15B |
| 2024 | 28,169 | 840,473 | 92,204 | $3.45B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Gilead Sciences | 840,772 | $3.46B |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.